How Micron Technology Could Benefit Healthcare Companies, Investors and the Economy
In addition to being a leader in the development of next-generation microelectronics and high-performance computing, Micron has also created the world’s first nanoscale biosensor that can detect microRNA, a small protein found in cells that can lead to cancer.
Micron and Biogen have teamed up to develop Micron BioRescue, a biosensor developed to test for microRNA before a patient is admitted to the hospital.
Microns BioRiscue can be used to diagnose patients early in the disease process and monitor the progression of the disease.
The device is the first to have a direct molecular-level detection of microRNA that has been tested against cancerous tumors.
Micronexus, a leading supplier of biosensors to health care systems, announced last week that it has agreed to develop and commercialize Micron bioRiscues as part of a larger R&D effort.
Micrones Microelectronics company Micron Technologies has developed a bioelectronic sensor that can measure and predict how a patient responds to various types of environmental stressors.
The company has partnered with BioMedtech, a startup based in Singapore, to develop a biosensory device that can be worn on the skin and monitor changes in the body’s immune system.
The Micron Microelectronic Sensors are the first products of this joint venture between Micron, BioMedTech and Micron that can monitor and predict changes in biological function that can then be measured in a clinical setting.
Micronics BioRscue, developed to detect microRNAs, is designed to be worn in the skin to monitor inflammation and the health of the immune system and is currently being tested in humans.
Micronic and BioMed are also working to create a biosignature device for the first time to measure the activity of a cancer cell.
The technology can be incorporated into existing bioelectronics to improve patient outcomes.
The bioelectrical sensor, which will be developed for use in bioelectrochemical devices, can detect the presence of microRNIs in blood samples, which can then help a patient with cancer control the progression and spread of the cancer.
MicroRNAs are proteins that have been found to be important in many cancers, such as leukemia, but are not yet identified in all cancers.
MicRON BioRSCues have already been approved by the FDA for use by patients with cancer and can also be used by healthcare workers in the event of a workplace accident.
Micropower and Micronexys Microelectrical Devices Micron announced on Wednesday that it will start production of its Micron Power Microelectrics (PME) power devices in 2020.
Microms PME products will be made by a joint venture with Micron’s own research lab in the United States, which is led by Dr. James T. Pomerantz, the former chief scientist at Micron.
The PME power devices will use Micron technology and be based on the company’s NanoPOWER microprocessor, which Micron is building in partnership with Samsung.
Micros Power Micron will use the company-developed NanoPowered microprocessor for its PME, and the chip will power the device, which has a battery life of up to 100 hours.
Microran Technologies Micron said it has partnered up with Bio-Radix Inc. (BRAX) to develop the company�s first nano-scale biosensor, called Micron NanoScan.
The biosensor can be attached to the skin, which enables the sensor to detect biological activity as it travels through the body.
Microwaves Micron already has an extensive portfolio of nano-electronic products in development, including a biosense device called Micronexes, which was unveiled last year.
MicroSystems Micron also announced last year that it is working with BioMatic Inc. to develop bioelectrics devices based on a platform that is similar to Micron�s NanoPower microprocessor.
BioMatics is a spin-out of BioRadix that Micron purchased for $4 billion in 2015.
BioMed Systems BioMed Technologies said it will create the first bioelectromechanical devices based around a biosensing platform.
The BioMed NanoPower will be the first device that will be used in a biofeedback system, a device that uses bioelectrophysiological signals from a patient�s skin to provide biofeedbacks to a device.
Micross and MicroTech Micron shares fell 1.7% to $39.84 on Wednesday, after initially hitting a high of $43.80.
The stock rose 0.4% to about $42.95 after the news broke.